{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation was not estimable as only one participant had a quantifiable pre-dose concentration; the remaining values were below the limit of quantification (BLQ).","groupId":"OG000","spread":"NA","value":"1070.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Cycle 1 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"430.172","value":"342.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Cycle 1 - End of infusion (30 min)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2251.734","value":"4038.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Cycle 1 - Day 3 (48 hr)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2682.503","value":"3664.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"Cycle 1 - Day 5 (96 hr)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"83.847","value":"94.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Cycle 2 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"142.401","value":"211.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Cycle 2 - End of infusion (30 min)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"502.966","value":"1799.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"Cycle 2 - Day 3 (48 hr)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"661.914","value":"1481.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Cycle 2 - Day 8 (168 hr)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.715","value":"91.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Cycle 3 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"251.617","value":"294.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Cycle 4 - 15 to 21 Days Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"91.718","value":"107.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Cycle 5 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"77.201","value":"103.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"Cycle 6 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"317.291","value":"329.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Cycle 6 - 15 to 21 Days Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"93.931","value":"118.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Cycle 7 - Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"200.011","value":"241.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Cycle 8 - 15 to 21 Days Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"267.333","value":"286.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Last - 15 to 21 Days Postdose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"The plasma concentration of MMAE is a critical factor in determining the efficacy and safety of ADCs.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\\^2 and doxorubicin 50 mg/m\\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.","id":"OG000","title":"Brentuximab Vedotin + CHP"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic analysis set comprised of all participants who are in the FAS with at least 1 pharmacokinetic parameter. Here, \"number analyzed\" are the number of participants with data available for analysis at specified time-point.","reportingStatus":"POSTED","timeFrame":"Cycle 1:Predose on Day1 and at 30minutes (min),48and 96hours postdose;Cycle 2:Predose on Day1 and at 30min,48 and 168hours postdose;Predose on Day1 of Cycles3,5,6,7;Anytime once on Days15,21 of Cycles4,6,8;30 days post-last dose; each cycle=21days","title":"Plasma Monomethyl Auristatin E (MMAE) Concentration","type":"SECONDARY","unitOfMeasure":"picogram per milliliter (pg/mL)"}